Targinta

Targinta is a preclinical stage oncology biotech company, developing first-in-class tumor-targeting antibodies and antibody-drug conjugates (ADCs) for aggressive cancers based on the in-house discovery of the novel patent-protected cancer target integrin α10β1. The pipeline includes TARG10, a function-blocking intergrin α10-antibody that is being developed to prevent metastasis, and TARG9, an intergrin α10-ADC that is armed with a powerful toxin that selectively kills tumor cells. Targinta is a wholly owned subsidiary of Xintela AB (publ) and is headquartered in Lund, Sweden.